ARCpoint Labs
Franchise Information
Analyzed filing: MN · File #441424892
Filed: Jun 22, 2026
FDD Issued: May 8, 2026
Extracted: Aug 23, 2026
Needs review
family consensus fee low tie:family=mn:36601-202605|values=39500,54500|current=39500
family consensus auv tie:family=mn:36601-202605|values=266753,266754|current=266754
Franchisor Details
ARCpoint Franchise Group, LLC
Cresso Brands, LLC
303 Perimeter Center North, Suite 575, Atlanta, GA 30346
(864) 271-3210
2005
Industry & Qualifications
Health & Medical
10.0%
$39,500 - $54,500
7.0%
Ad Fund: 2.0%
$166K - $310K
10 years
Renewable
Outlet Information
118
118
+17
-23
Churn Breakdown (Last Year)
1
0
22
6
0
Disclosed
Data represents Gross Sales minus clinical program sales for 83 franchised ARCpo...
Financial Performance (Item 19)
$266,754
$200,218
$1,315,483
54.2%
83 units
Legal History
Yes
Rachel DeMara arbitration settled with $175,000 paid to franchisee and mutual termination; lawsuits...
None
| Number | File name | Source State | Filing Date | Actions |
|---|---|---|---|---|
| 5653 |
CA_APP00005653.pdf
Alternate source copy
· newest filing
|
CA | Jul 8, 2026 | |
| 441424892 |
MN_36601-202605-11_arcpoint-franchise-group,-llc.pdf
Canonical 2026 analysis
· needs review
|
MN | Jun 22, 2026 | |
| 1124905510 |
MN_36601-202605-10_arcpoint-franchise-group,-llc.pdf
Alternate source copy
|
MN | Jun 22, 2026 | |
| 421297225 |
MN_34610-202508-11_arcpoint-franchise-group,-llc.pdf
Canonical 2025 analysis
· needs review
|
MN | Sep 9, 2025 | |
| 974557738 |
MN_34610-202508-10_arcpoint-franchise-group,-llc.pdf
Alternate source copy
|
MN | Sep 9, 2025 | |
| 262525 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Virginia_262525.pdf
Alternate source copy
|
VA | Aug 8, 2025 | |
| 252478 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_South Dakota_252478.pdf
Alternate source copy
|
SD | Aug 8, 2025 | |
| 262683 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_New York_262683.pdf
Alternate source copy
|
NY | Aug 8, 2025 | |
| 256761 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_North Dakota_256761.pdf
Alternate source copy
|
ND | Aug 8, 2025 | |
| 259888 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Maryland_259888.pdf
Alternate source copy
|
MD | Aug 8, 2025 | |
| 253241 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Illinois_253241.pdf
Alternate source copy
|
IL | Aug 8, 2025 | |
| 639586 |
639586_arcpoint-franchise-group--llc.pdf
Alternate source copy
|
WI | Aug 8, 2025 | |
| 31014 |
CA_31014.pdf
Alternate source copy
|
CA | Jan 6, 2025 | |
| 33014 |
CA_33014.pdf
Alternate source copy
|
CA | Jan 6, 2025 | |
| 1734924685 |
MN_32283-202408-05_arcpoint-franchise-group,-llc.pdf
Alternate source copy
|
MN | Sep 24, 2024 | |
| 1473833258 |
MN_32283-202408-04_arcpoint-franchise-group,-llc.pdf
Canonical 2024 analysis
· needs review
|
MN | Sep 24, 2024 | |
| 218008079 |
MN_31025-202404-07_arcpoint-franchise-group,-llc.pdf
Alternate source copy
|
MN | May 10, 2024 | |
| 27139 |
CA_27139.pdf
Alternate source copy
|
CA | Apr 12, 2024 | |
| 175940 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Virginia_175940.pdf
Alternate source copy
|
VA | Apr 8, 2024 | |
| 184139 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_New York_184139.pdf
Alternate source copy
|
NY | Apr 8, 2024 | |
| 175755 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_North Dakota_175755.pdf
Alternate source copy
|
ND | Apr 8, 2024 | |
| 176939 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Maryland_176939.pdf
Alternate source copy
|
MD | Apr 8, 2024 | |
| 198628 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_California_198628.pdf
Alternate source copy
|
CA | Apr 8, 2024 | |
| 146002 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Virginia_146002.pdf
Alternate source copy
|
VA | Apr 8, 2024 | |
| 150427 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_New York_150427.pdf
Alternate source copy
|
NY | Apr 8, 2024 | |
| 147373 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_North Dakota_147373.pdf
Alternate source copy
|
ND | Apr 8, 2024 | |
| 93468 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Virginia_93468.pdf
Canonical 2023 analysis
|
VA | Mar 31, 2023 | |
| 123777 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_New York_123777.pdf
Alternate source copy
|
NY | Mar 31, 2023 | |
| 94333 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_North Dakota_94333.pdf
Alternate source copy
|
ND | Mar 31, 2023 | |
| 116994 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Virginia_116994.pdf
Alternate source copy
|
VA | Mar 31, 2023 | |
| 109632 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_New York_109632.pdf
Alternate source copy
|
NY | Mar 31, 2023 | |
| 98995 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_North Dakota_98995.pdf
Alternate source copy
|
ND | Mar 31, 2023 | |
| 109156 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Maryland_109156.pdf
Alternate source copy
|
MD | Mar 31, 2023 | |
| 23365 |
CA_23365.pdf
Alternate source copy
|
CA | Mar 30, 2022 | |
| 14969 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_Virginia_14969.pdf
Alternate source copy
|
VA | Mar 21, 2022 | |
| 18291 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_New York_18291.pdf
Alternate source copy
|
NY | Mar 21, 2022 | |
| 13413 |
436145_Franchise__ARCpoint_Labs_EFDID__436145_North Dakota_13413.pdf
Canonical 2022 analysis
|
ND | Mar 21, 2022 | |
| 20312 |
CA_20312.pdf
Canonical 2021 analysis
|
CA | Sep 15, 2021 | |
| 18120 |
CA_18120.pdf
Canonical 2020 analysis
|
CA | Jun 22, 2020 | |
| 15340 |
CA_15340.pdf
Canonical 2019 analysis
|
CA | Jun 21, 2019 | |
| 12071 |
CA_12071.pdf
Canonical 2018 analysis
|
CA | Aug 31, 2018 | |
| 8801 |
CA_8801.pdf
Canonical 2017 analysis
|
CA | Jun 2, 2017 | |
| 5319 |
CA_5319.pdf
Canonical 2016 analysis
|
CA | Apr 18, 2016 |
Prev
Page 1 of 1
Next